Compare IDA & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDA | ARWR |
|---|---|---|
| Founded | 1915 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 9.3B |
| IPO Year | 1998 | 2009 |
| Metric | IDA | ARWR |
|---|---|---|
| Price | $141.78 | $76.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $142.86 | $83.40 |
| AVG Volume (30 Days) | 422.4K | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 7.27 | ★ 99.80 |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $1,746,972,000.00 | $16,142,321.00 |
| Revenue This Year | $10.92 | N/A |
| Revenue Next Year | $7.71 | N/A |
| P/E Ratio | $24.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $111.12 | $14.30 |
| 52 Week High | $149.73 | $82.26 |
| Indicator | IDA | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 54.92 |
| Support Level | $139.58 | $70.79 |
| Resistance Level | $145.08 | $76.45 |
| Average True Range (ATR) | 2.35 | 4.10 |
| MACD | -0.52 | -0.65 |
| Stochastic Oscillator | 26.72 | 49.23 |
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The company's only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which are involved in food processing, electronics and general manufacturing, agriculture, health care, government, education, and information technology.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.